In February, the Rubizhne branch of the pharmaceutical company Microkhim donated charitable assistance to the Institute of Cardiology named after academician N.D. Strazhesko of the National Academy of Medical Sciences of Ukraine. In particular, the Microkhim team donated to the Institute preparations for the treatment of pulmonary arterial hypertension in the total amount of 200 thousand hryvnias.
The provision of charitable assistance aimed at ensuring access for patients with this orphan disease to a modern high-quality domestic drug has become a practical part of the implementation of the Memorandum of Cooperation between structures signed earlier. At the same time, the cooperation, which is carried out within the framework of the Microkhim charity program “We Make the Best Better Accessible”, in the future involves the development of individual approaches to the treatment of some orphan diseases based on the widespread introduction of therapeutic drug monitoring techniques.
As experts of the Institute of Cardiology named after academician N.D. Strazhesko, Microkhim products will completely cover the annual need of patients with pulmonary arterial hypertension undergoing treatment in the department of symptomatic hypertension of the institution, in specialized preparations based on sildenafil.
“The help of a pharmaceutical company is really very important for our patients. The fact is that patients with pulmonary arterial hypertension drugs are provided by the state. However, public procurement takes place on the basis of need formed at the beginning of the year. Thus, patients with a newly diagnosed disease can be included in the lists for the provision of drugs only from the next reporting year. And given the rather high prices for drugs for the treatment of orphan diseases, this becomes a serious problem for patients, ”said Irina Zhivilo, a specialist of the Institute.
In this regard, the Microkhim team, represented by the director of the marketing department, Victoria Kostyuk, expressed readiness, if necessary, to make additional deliveries of drugs to treat this category of patients. At the same time, the head of marketing department of the pharmaceutical company noted that “socially responsible representatives of the pharmaceutical community are always ready for cooperation and dialogue in the interests of the patient. However, the situation on the market of medicines for the treatment of orphan diseases requires a greater involvement of the state in the mechanics of the process. Especially in the part concerning the development of an effective and efficient mechanism for the transfer of the drug from a pharmaceutical company to a patient through a network of medical facilities. On behalf of the Microkhim team, I would like to thank the Institute of Cardiology, which together with us shared the functions of providing patients with pulmonary arterial hypertension with a high-quality domestic product.”